Myriad(MYGN) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights SALT LAKE CITY, November 3, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed its financial guidance on business performance for the full-year 2025. "I am pleased with our solid results for the quart ...